2. Academic Validation
  3. A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis

A strategy for the design of multiplex inhibitors for kinase-mediated signalling in angiogenesis

  • Curr Opin Chem Biol. 2002 Aug;6(4):486-92. doi: 10.1016/s1367-5931(02)00357-5.
Jerry Adams 1,  Pearl Huang,  Denis Patrick
Affiliations

Affiliation

  • 1 GlaxoSmithKline MMPD CEDD Departments Oncology and Medicinal Chemistry, Upper Merion, King of Prussia, Philadelphia, PA 19406, USA. jerry_I_adams@gsk.com
PMID: 12133725 DOI: 10.1016/s1367-5931(02)00357-5
Abstract

Tumour growth is dependent on multiple factors, including the physiological process of angiogenesis. Several opportunities for inhibiting angiogenesis with targeted therapies have been identified and are currently being evaluated for clinical efficacy. Some of the most promising approaches include small-molecule inhibitors for the tyrosine receptor kinase VEGFR2/KDR/Flk-1. Other signal-transduction pathways have also been shown to regulate angiogenesis, including FGFR, PDGFR, Tie and EphB.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-15973
    Tie2 Inhibitor
    Tie